There are 2949 resources available
1254P - Radical radiotherapy (RT) and chemoradiotherapy (CRT) in non-small cell lung cancer (NSCLC): Outcomes from a regional cancer network
Presenter: Mohammed Abdul-Latif
Session: E-Poster Display
Resources:
Abstract
1255TiP - CheckMate 73L: A phase III study comparing nivolumab (NIVO) plus concurrent chemoradiotherapy (CCRT) followed by NIVO ± ipilimumab (IPI) versus CCRT followed by durvalumab (DURV) for previously untreated, locally advanced (LA) stage III non-small cell lung cancer (NSCLC)
Presenter: Dirk De Ruysscher
Session: E-Poster Display
Resources:
Abstract
1256TiP - Phase III study of pembrolizumab (Pembro) with concurrent chemoradiation therapy (CCRT) followed by pembro with or without olaparib (Ola) vs CCRT followed by durvalumab (Durva) in unresectable, locally advanced, stage III non-small cell lung cancer (NSCLC): KEYLYNK-012
Presenter: Salma Jabbour
Session: E-Poster Display
Resources:
Abstract
1262P - Randomized, open-label phase III study of pembrolizumab (pembro) vs docetaxel (doce) in patients (pts) with previously treated NSCLC with PD-L1 tumour proportion score (TPS) ≥1%: KEYNOTE-033
Presenter: Caicun Zhou
Session: E-Poster Display
Resources:
Abstract
1263P - Tislelizumab + chemotherapy vs chemotherapy alone as first-line treatment for locally advanced/metastatic nonsquamous NSCLC
Presenter: Shun Lu
Session: E-Poster Display
Resources:
Abstract
1264P - Updated analysis of tislelizumab plus chemotherapy vs chemotherapy alone as first-line treatment of advanced squamous non-small cell lung cancer (SQ NSCLC)
Presenter: Jie Wang
Session: E-Poster Display
Resources:
Abstract
1265P - IMpower150: A post hoc analysis of efficacy outcomes in patients with KRAS, STK11 and KEAP1 mutations
Presenter: Howard West
Session: E-Poster Display
Resources:
Abstract
1266P - Initial results from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected first-line metastatic non-small cell lung carcinoma
Presenter: Margarita Majem
Session: E-Poster Display
Resources:
Abstract
1267P - Efficacy of camrelizumab (SHR-1210) plus apatinib as second-line treatment for advanced squamous NSCLC
Presenter: Guanghui Gao
Session: E-Poster Display
Resources:
Abstract
1268P - JASPER: Efficacy and safety of first-line (1L) niraparib plus a programmed death receptor 1 inhibitor (PD-1i) in patients with advanced non-small cell lung cancer (NSCLC)
Presenter: Suresh Ramalingam
Session: E-Poster Display
Resources:
Abstract